News Flash: 7 Analysts Think Crescent Biopharma, Inc. (NASDAQ:CBIO) Earnings Are Under Threat

Nov 20, 2026
news-flash:-7-analysts-think-crescent-biopharma,-inc.-(nasdaq:cbio)-earnings-are-under-threat

The latest analyst coverage could presage a bad day for Crescent Biopharma, Inc. (NASDAQ:CBIO), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Following the latest downgrade, the current consensus, from the seven analysts covering Crescent Biopharma, is for revenues of US$3.4m in 2027, which would reflect a painful 78% reduction in Crescent Biopharma’s sales over the past 12 months. Losses are presumed to reduce, shrinking 15% per share from last year to US$3.54. Yet before this consensus update, the analysts had been forecasting revenues of US$4.8m and losses of US$3.06 per share in 2027. So there’s been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

See our latest analysis for Crescent Biopharma

earnings-and-revenue-growth
NasdaqCM:CBIO Earnings and Revenue Growth November 20th 2026

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 70% annualised revenue decline to the end of 2027. That is a notable change from historical growth of 85% over the last year. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 21% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining – Crescent Biopharma is expected to lag the wider industry.

The Bottom Line

The most important thing to take away is that analysts increased their loss per share estimates for next year. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Given the serious cut to next year’s outlook, it’s clear that analysts have turned more bearish on Crescent Biopharma, and we wouldn’t blame shareholders for feeling a little more cautious themselves.

There might be good reason for analyst bearishness towards Crescent Biopharma, like major dilution from new stock issuance in the past year. Learn more, and discover the 1 other flag we’ve identified, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Leave a comment